论文部分内容阅读
摘要目的比较MRI表现和临床评估对于Ⅱ或Ⅲ期乳腺癌病人新辅助化疗(NACT)后病理反应的预测价值。材料与方法此项研究由美国放射学会和当地医院审查委员会批准,符合HIPAA要求,并获得病人的知情同意。2002年5月-2006年3月间,浸润性乳腺癌且肿块直径≥3cm的病人,接受规律性新辅助化疗,采
Abstract Objective To compare the predictive value of MR imaging and clinical assessment for the pathological response to neoadjuvant chemotherapy (NACT) in patients with stage II or III breast cancer. Materials and Methods The study was approved by the American College of Radiology and the local hospital review board, meets HIPAA requirements and obtained patient informed consent. May 2002 - March 2006, infiltrating breast cancer and mass diameter ≥ 3cm patients received regular neoadjuvant chemotherapy, mining